Cryo-Cell International (CCEL) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cryo-Cell International faces significant uncertainty regarding the outcome of its arbitration demand against Duke, filed with the American Arbitration Association. The company alleges multiple breaches, including fraudulent inducement and violations of North Carolina’s Unfair Trade Practices Act. With Duke yet to respond as of mid-October 2024, Cryo-Cell cannot predict the arbitration’s outcome, timing, or potential defenses and counterclaims Duke might assert. The inherent unpredictability and high costs of litigation pose a material risk to Cryo-Cell’s financial position and business operations.
Overall, Wall Street has a Moderate Buy consensus rating on CCEL stock based on 1 Buy.
To learn more about Cryo-Cell International ‘s risk factors, click here.